BTK and neoplasm: Pirtobrutinib’s reversible binding, BTK selection, high effectiveness, attractive pharmacological characteristics, and satisfactory clinical results in patients with wild-type or mutant BTK indicated it might be used to treat any BTK-driven tumor [161].